Can Obama Help Vete...
Health Care: Drugs
Affymax Inc. (AFFY: NASDAQ)
$13.35 -0.79 | -5.59%
06/01/12 - 04:00 PM ET
Company Cash Flow
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -61.37M | -14.08M | -76.53M | -86.51M |
| Operating Gains/Losses | 11.00K | 2.00K | -292.00K | -132.00K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -6.94M | 20.00M | 4.35M | -9.02M |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 2.00M | 0.00 | 3.33M | 0.00 |
| (Decrease) Increase In Payables | 620.00K | -143.00K | -150.00K | -8.73M |
| (Decrease) Increase In Other Current Liabilities | -19.34M | -82.73M | -23.57M | 25.52M |
| (Increase) Decrease In Other Working Capital | 588.00K | 6.64M | 414.00K | -1.79M |
| Other Non-Cash Items | 10.02M | 11.52M | 11.41M | 10.92M |
| Net Cash From Continuing Operations | -71.97M | -49.23M | -80.93M | -62.63M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -71.97M | -49.23M | -80.93M | -62.63M |
| Sale of Property, Plant & Equipment | 0.00 | 2.00K | 18.00K | 22.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 79.24M | 124.28M |
| Purchases of Property, Plant & Equipment | -1.26M | -730.00K | -716.00K | -3.78M |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | -29.34M | -143.15M |
| Other Cash from Investing Activities | 41.00K | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 8.00M | -11.48M | 49.19M | -22.63M |
| Issuance of Debt | 0.00 | 0.00 | 9.19M | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 54.80M | 8.11M | 123.79M | 1.22M |
| Repayment of Long-Term Debt | 0.00 | -9.19M | 0.00 | -132.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | -1.00K | -1.00K |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 54.80M | -1.08M | 132.98M | 1.09M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -9.16M | -61.80M | 101.25M | -84.17M |
Portfolios with AFFY
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- UserBurrdee
- ContributorStocks At New 52-Week Highs...
- Usersimulator
- Contributor10 Biotech Stocks on Clinic...
- UserPART 5 JPMorgan 28th Annual...
Latest AFFY Headlines from TheStreet
- 8 Stocks Rising on Monster Volume 04.02.12 | 01:04 pm
- Biotech Stock Mailbag: MAP Pharma, Affymax 03.30.12 | 05:03 am
- 8 Stocks Rising on Huge Volume 03.23.12 | 02:03 pm
- Biotech Stock Mailbag: Xoma's Big Backers, FDA Approvals Contest 03.23.12 | 05:03 am
- The Next Big Thing in Biotech: FDA Decisions
03.23.12 | 05:03 am - Biotech Stock Chat: Recap 03.15.12 | 11:03 am
- 5 Stocks Ready to Soar on Bullish Earnings 03.13.12 | 06:03 am
- More Biotech Twitter Mailbag: Orexigen, Affymax, YM Bio, Spectrum & More 02.29.12 | 07:02 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- 6 Stocks at New 52-Week Highs 02.14.12 | 02:02 pm
Press Releases for AFFY
- Affymax To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 06.01.12 | 08:06 am
- Affymax Reports First Quarter 2012 Financial Results - Business Wire 05.07.12 | 04:05 pm
- Affymax And Takeda Announce Centers For Medicare And Medicaid Services Has Assigned A Q-Code For OMONTYS® (Peginesatide) Injection - Business Wire 04.13.12 | 08:04 am
- Affymax Receives A $50 Million Milestone Payment For U.S. Approval Of OMONTYS® (peginesatide) Injection - Business Wire 04.09.12 | 04:04 pm
- Affymax And Takeda Announce FDA Approval Of OMONTYS® (Peginesatide) Injection For The Treatment Of Anemia Due To Chronic Kidney Disease (CKD) In Adult Patients On Dialysis - Business Wire 03.27.12 | 02:03 pm
- Affymax® Reports Year End 2011 Financial Results - Business Wire 03.14.12 | 04:03 pm
- Affymax Announces Yearend 2011 Financial Results Teleconference And Webcast - Business Wire 03.07.12 | 04:03 pm
- Affymax To Receive $5 Million Milestone Payment For Acceptance Of European Marketing Authorization Application For Peginesatide - Business Wire 02.27.12 | 08:02 am
- Affymax Announces Upcoming Webcasts And Conference Participation - Business Wire 02.21.12 | 04:02 pm
- Affymax To Present At 14th Annual BIO CEO & Investor Conference - Business Wire 02.08.12 | 04:02 pm
Partner Headlines for AFFY
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 05.23.12 | 09:05 am
- The Definitive Biotech ETF Guide (IBB, XBI, FBT) - Benzinga 05.21.12 | 01:05 pm
- Amgen Beats but Maintains Outlook - Analyst Blog - Zacks 04.25.12 | 10:04 am
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Cramer's Lightning Round - Danaher Has Good Blood Lines (2/10/12) - Seeking Alpha 02.12.12 | 07:02 am
- Affymax Spiking Higher on Heavy Volume - Benzinga 12.27.11 | 01:12 pm
- 7 Stocks With Unusual Options Activity - Seeking Alpha 12.09.11 | 09:12 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Company News for December 6, 2011 - Corporate Summary - Zacks 12.06.11 | 10:12 am
